Earlier measured awakening after the switch was distinct from an unrestricted earlier discharge policy.
The retrospective ERCP study compared eighty-eight remimazolam procedures with eighty-six midazolam procedures. Midazolam was used during April through July 2025 and remimazolam during August through November. Median postprocedure awakening was about two versus four minutes, and antagonist use was lower with remimazolam. Sedation success and recorded adverse-event frequency did not clearly differ. Patients were nevertheless kept in bed for at least two hours.
The sequential calendar periods allow changes in staff, case mix or practice to influence results. Few patients had severe ASA classifications. A short awakening endpoint does not establish earlier actual departure, restored psychomotor function or lower delayed-event risk. The background pethidine and local sedation workflow remain part of the comparison.
An efficiency claim should state whether it concerns awakening, readiness scoring, mandatory observation or actual discharge. Those endpoints can have different practical meanings. This study supports a measured awakening advantage after a service-level sedative change, with important temporal confounding. It cannot establish that a particular patient could safely leave after two minutes or that a later adverse event was unrelated to sedation because initial awakening was rapid.
Source: PMC12796972, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Three-Drug ERCP Sedation Compared Age Groups Rather Than Isolated Medicines.